Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain

Open access
Ruiz-Moreno, José M., Gámez Lechuga, María, Calvo, Pilar, Merino, María, Martín Lorenzo, Teresa, Maravilla-Herrera, Paulina, Gil Jiménez, Beatriz, Abraldes, Maximino J. · 2024 · Ophthalmology and Therapy

Abstract

INTRODUCTION: Diabetic macular oedema (DMO) is a complication of diabetic retinopathy that can result in vision loss. The disease can impact different spheres of a patient's life, including physical and psychological health, work, and activities of daily living, entailing an important use of healthcare and non-healthcare resources. This study aimed to estimate the socio-economic burden of DMO in Spain. METHODS: The burden of DMO was estimated from a societal perspective, per patient, year of treatment since diagnosis, and type of treatment. Four categories were considered: direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labour productivity losses (LPL), and intangible costs (IC) associated with loss of quality of life. Average annual costs were calculated by multiplying the resources used per patient by their corresponding unit price (or financial proxy). For a more accurate estimation, differences in resource use between treatments (intravitreal anti-vascular endothelial growth factor injections of ranibizumab or aflibercept, and intravitreal dexamethasone implants) and year since diagnosis (first, second, and third year or beyond) were considered and presented separately. The reference year for costs was 2021. RESULTS: The average annual costs of DMO in the first year of treatment after diagnosis was estimated at €18,774, €17,512, and €16,188 per patient treated with ranibizumab, aflibercept, and dexamethasone, respectively. This burden would be reduced to €15,783, €15,701, and €12,233 in the second year, and to €15,119, €15,043, and €12,790 in the third year, respectively. Diagnosis of DMO entails an additional one-off cost of €485. DHC accounted for the greatest proportion of total annual costs per patient, independent of the year, with LPL also making an important contribution to total costs. CONCLUSIONS: The socio-economic impact of DMO on patients, the healthcare system, and society at large is substantial. The constant increase in its prevalence accentuates the need for planning and implementation of healthcare strategies to prevent vision loss and reduce the socio-economic burden of the disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40123-024-00959-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Burden of DMO study design. DMO diabetic macular oedema. *One-off cost not included in the total cost
Fig. 1 Burden of DMO study design. DMO diabetic macular oedema. *One-off cost not included in the total costCC BY-NC · PubMed Central
Fig. 2 Year 1 of treatment for patients with DMO that are refractory to three loading doses of intravitreal anti-VEGF injections and switch to dexamethasone intravitreal implants. DMO diabetic macular oedema
Fig. 2 Year 1 of treatment for patients with DMO that are refractory to three loading doses of intravitreal anti-VEGF injections and switch to dexamethasone intravitreal implants. DMO diabetic macular oedemaCC BY-NC · PubMed Central
Fig. 3 Total costs per patient stratified by treatment and year since diagnosis (2021 €). Error bars represent the results of the sensitivity analysis
Fig. 3 Total costs per patient stratified by treatment and year since diagnosis (2021 €). Error bars represent the results of the sensitivity analysisCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 7

Metadata

Authors
Ruiz-Moreno, J. M., Gámez Lechuga, M., Calvo, P., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Abraldes, M. J.
Affiliations
  • Hospital Universitario Miguel Servet (ES)
  • Weber (ES)
  • Complejo Hospitalario Universitario de Santiago (ES)
Corresponding author
Merino, María
Venue
Ophthalmology and Therapy
Published
2024-05-21
Volume
13
Issue
7
Pages
1937-1953
ISSN
  • 2193-6528 (ISSN-L)
  • 2193-8245
OpenAlex
W4398156667
Cited by
7
References
30
Citations by year
2026: 3 · 2025: 3 · 2024: 1
FWCI
2.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Ophthalmology and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Roche Farma S.A.
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
diabetic macular edema, socioeconomic burden, health care costs, direct healthcare costs, labour productivity loss, quality of life, ranibizumab, aflibercept, intravitreal dexamethasone implant, intravitreal anti-VEGF therapy, vision loss, Spain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain. https://app.cochat.ai/papers/10.1007/s40123-024-00959-2
The paper
Ruiz-Moreno, J. M., Gámez Lechuga, M., Calvo, P., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Abraldes, M. J. (2024). Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-024-00959-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.